10.25384/SAGE.11417742.v1 Vincenzo Adamo Vincenzo Adamo Giuseppina Rosaria Rita Ricciardi Giuseppina Rosaria Rita Ricciardi Dario Giuffrida Dario Giuffrida Giuseppa Scandurra Giuseppa Scandurra Antonio Russo Antonio Russo Livio Blasi Livio Blasi Pietro Spadaro Pietro Spadaro Carmelo Iacono Carmelo Iacono Hector J. Soto Parra Hector J. Soto Parra Antonino Savarino Antonino Savarino Francesco Ferraú Francesco Ferraú Filippo Zerilli Filippo Zerilli Francesco Verderame Francesco Verderame Alfredo Butera Alfredo Butera Carlo Santangelo Carlo Santangelo Veronica Franchina Veronica Franchina Michele Caruso Michele Caruso TAM895755_Supplementary_material_CLN – Supplemental material for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study SAGE Journals 2019 eribulin metastatic breast cancer multicentre prospective real world third line 2019-12-20 13:07:16 Journal contribution https://sage.figshare.com/articles/journal_contribution/TAM895755_Supplementary_material_CLN_Supplemental_material_for_Eribulin_mesylate_use_as_third-line_therapy_in_patients_with_metastatic_breast_cancer_VESPRY_a_prospective_multicentre_observational_study/11417742 <p>Supplemental material, TAM895755_Supplementary_material_CLN for Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study by Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Dario Giuffrida, Giuseppa Scandurra, Antonio Russo, Livio Blasi, Pietro Spadaro, Carmelo Iacono, Hector J. Soto Parra, Antonino Savarino, Francesco Ferraú, Filippo Zerilli, Francesco Verderame, Alfredo Butera, Carlo Santangelo, Veronica Franchina and Michele Caruso in Therapeutic Advances in Medical Oncology</p>